Agonist-Induced Activation of Matrix Metalloproteinase-7 Promotes Vasoconstriction Through the Epidermal Growth Factor–Receptor Pathway
- 9 January 2004
- journal article
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 94 (1) , 68-76
- https://doi.org/10.1161/01.res.0000109413.57726.91
Abstract
Matrix metalloproteinase (MMP)-dependent shedding of heparin-binding epidermal growth factor (HB-EGF) and subsequent activation of the EGF receptor (EGFR) in the cardiovasculature is emerging as a unique mechanism signaling growth effects of diverse G protein–coupled receptors (GPCRs). Among these GPCRs are adrenoceptors and angiotensin receptors that contribute to the pathogenesis of hypertension through their vasoconstrictive and growth effects. Focusing on α1b-adrenoceptors, we suggest here that MMP-dependent activation of the EGFR promotes vasoconstriction as well as growth. We identified MMP-7 as a major HB-EGF sheddase in rat mesenteric arteries and α1b-adrenoceptors, angiotensin receptors, and hypertension-stimulated MMP-7 activity. Adrenoceptors stimulated EGFR autophosphorylation in arteries, and this transactivation was opposed by the MMP-7 inhibitor GM6001 as well as MMP-7–specific antibodies. In isolated microperfused arteries, blockade of EGFR transactivation with inhibitors of the EGFR (AG1478 and PD153035), HB-EGF (CRM197 and neutralizing antibodies), or MMPs (doxycycline) inhibited adrenergic vasoconstriction. In spontaneously hypertensive rats but not in normotensive rats, the inhibition of MMPs with doxycycline (19.2 mg/d from week 7 until week 12) reduced systolic blood pressure and attenuated HB-EGF shedding in the mesenteric arteries. These findings suggest a previously unknown mechanism of vasoregulation whereby agonists of certain GPCRs (such as adrenoceptors and angiotensin receptors) activate MMPs (such as MMP-7) that shed EGFR ligands (such as HB-EGF), which then activate the EGFR, thereby promoting vasoconstriction as well as growth. Because this mechanism is triggered by agonists typically overexpressed in hypertension, its blockade may have therapeutic potential for simultaneously inhibiting pathological vasoconstriction and growth in hypertensive disorders.Keywords
This publication has 22 references indexed in Scilit:
- Antisense to Epidermal Growth Factor Receptor Prevents the Development of Left Ventricular HypertrophyHypertension, 2003
- Recent advances in intracellular signalling in hypertensionCurrent Opinion in Nephrology and Hypertension, 2003
- Proximal Events in Signaling by Plasma Membrane Estrogen ReceptorsJournal of Biological Chemistry, 2003
- Epidermal growth factor receptor transactivation mediates the tonic and fibrogenic effects of endothelin in the aortic wall of transgenic miceThe FASEB Journal, 2002
- The WRP component of the WAVE-1 complex attenuates Rac-mediated signallingNature Cell Biology, 2002
- The metalloprotease Kuzbanian (ADAM10) mediates the transactivation of EGF receptor by G protein–coupled receptorsThe Journal of cell biology, 2002
- Tumor Necrosis Factor-α Converting Enzyme (TACE) Regulates Epidermal Growth Factor Receptor Ligand AvailabilityJournal of Biological Chemistry, 2002
- CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodelingGenes & Development, 2002
- Cell communication networks: epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmissionOncogene, 2001
- Protein kinase C mediation of Ca2+-independent contractions of vascular smooth muscleBiochemistry and Cell Biology, 1996